|
Dr. Schwartz is Senior Vice President for Medical and Regulatory Affairs and Chief Medical Officer and has served in this capacity since June 2006. He joins ZIOPHARM with impressive drug development registration experience from the pharmaceutical industry with both Bayer Healthcare and Leo Laboratories. Over the last six years, Dr. Schwartz has focused on oncology clinical development of novel cytostatic, cytotoxic and immunological agents, achieving Awards for Excellence from both employers. At Bayer, he was the key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful phase III trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval on December 20, 2005. Dr. Schwartz has extensive regulatory experience in working with the FDA Oncology Division, the European Medicines Evaluation Agency (EMEA), and numerous other health authorities. | 